The first-generation of EGFR inhibitors, Gefitinib and Erlotinib, as well as the second-generation EGFR inhibitor Afatinib, showed the ability to efficiently inhibit GBM cell growth, division, and angiogenesis in in vitro studies [60]. This evidence concerns the gene EGFR and glioblastoma.